India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations 
Taiwan Urges Stronger Trade Ties With Fellow Democracies, Rejects Economic Dependence on China 
South Korea Factory Activity Hits 18-Month High as Export Demand Surges 
IMF Forecasts Global Inflation Decline as Growth Remains Resilient 
Japan’s Agricultural, Forestry and Fishery Exports Hit Record High in 2025 Despite Tariffs 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
JPMorgan Lifts Gold Price Forecast to $6,300 by End-2026 on Strong Central Bank and Investor Demand 
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors 
Gold, Silver, and Platinum Rally as Precious Metals Recover from Sharp Selloff 
Indian Rupee Strengthens Sharply After U.S.-India Trade Deal Announcement 
Asian Currencies Strengthen as Indian Rupee and Australian Dollar Rally 
Oil Prices Slide Nearly 3% as U.S.-Iran Talks Ease Geopolitical Tensions 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Moderna has filed a lawsuit against Pfizer and BionNTech over its mRNA technology that was used to produce COVID-19 vaccines. The American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, is suing for patent infringement, and this was filed last week.
Moderna also publicly announced its move to go after Pfizer and BioNTech as it believes that the latter copied its technology to make the COVID-19 vaccine Comirnaty. The company said it had filed patents for this between 2010 and 2016.
The patents were said to cover the company’s mRNA technology which is groundbreaking science that was important to the development of Moderna's mRNA COVID-19 vaccine called the Spikevax.
"We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic," Stephane Bancel, Moderna’s chief executive officer, said in a press release. "This foundational platform, which we began building in 2010, along with our patented work on coronaviruses in 2015 and 2016, enabled us to produce a safe and highly effective COVID-19 vaccine in record time after the pandemic struck.”
In response, Pfizer said that the lawsuit against them was unexpected and denied it had infringed any of Moderna’s patents. Pfizer and BionNTech said they have not yet fully reviewed the surprising complaint but vowed they would face the litigation to defend and quash all the allegations concerning patent infringement.
In a written statement that was sent to CNN, Pfizer further said that they are confident in their intellectual property as their own COVID-19 vaccine was based on BioNTech's proprietary mRNA technology. The vaccine was also co-developed by Pfizer and BioNTech.
BioNTech said in a statement that it is aware of the reports that it was sued and accused of copying some patents from Moderna. The company firmly stated that all of its work is original, so it will vigorously defend against these patent infringement allegations.
Meanwhile, Moderna said that while it has sued Pfizer and BioNTech, it is not aiming to pull out Pfizer's COVID-19 vaccine from the market. It is not planning to stop its future sales or seek damages for its sale, and what Moderna wants is simply a cut of its competitor's profits, as per Christopher Morten, who is an intellectual property law expert at Columbia University.
